This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • HIV/AIDS  • Pregnancy and Breast Feeding  • Occupational and Environmental Medicine  • Adverse Effects  • Alert me on articles by topic

JAMA. 2008;299(12):1421.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2007;56:1291-1292

In 1996, the U.S. Public Health Service first recommended using antiretrovirals as postexposure prophylaxis (PEP) after occupational exposure to human immunodeficiency virus (HIV).¹ Since the updated HIV PEP recommendations in 2005,² two important changes to antiretroviral use have occurred that affect the management of occupational exposures.

First, Kaletra® (Abbott Laboratories, Abbott Park, Illinois), a combination protease inhibitor, is no longer available in its original formulation: capsules containing 133 mg of lopinavir and 33 mg of ritonavir. Although the recommended daily prescribed amount of Kaletra ingredients is unchanged, the dosing regimen has changed as a result of the new Kaletra formulation. The previous dosing regimen for the capsule formulation was three capsules twice daily. Kaletra is now manufactured only in tablet form, with each tablet containing 200 mg of lopinavir and 50 mg of ritonavir. To achieve the same recommended daily prescribed amount of the tablet formulation, two tablets . . . [Full Text of this Article]